Literature DB >> 23776775

Ameloblastic carcinoma: A case report and literature review.

Manas Madan1, Jasbir Singh, Rachna Arora, Monika Bansal.   

Abstract

Ameloblastic carcinoma (AC) is a rare epithelial odontogenic tumor of the jaws, which exhibits cytological features of ameloblastoma and carcinoma. It has a distinct predilection for mandible. These lesions may initially show histologic features of ameloblastoma that dedifferentiate over time. Others may present with features of epithelial dedifferentiation in ameloblastoma. A case of ameloblastomic carcinoma in a 64-year-old male is reported, who presented with swelling in the left mandible 3 months after the extraction of the left upper molar.

Entities:  

Keywords:  Ameloblastoma; carcinoma; odontogenic

Year:  2011        PMID: 23776775      PMCID: PMC3657954          DOI: 10.4103/2229-516X.81983

Source DB:  PubMed          Journal:  Int J Appl Basic Med Res        ISSN: 2229-516X


INTRODUCTION

Ameloblastoma is a benign but locally aggressive neoplasm which clinically presents as a slowly growing painless swelling of the jaw. Eighty percent of it arises in the mandible.[1] It may present as a cystic lesion with benign clinical features or as a large tissue mass with ulceration, significant bone resorption and tooth mobility.[2] The typical ameloblastoma may show a variety of histologic patterns, namely, follicular, plexiform, acanthomatous, basal cell, and granular cell types. These patterns do not have a distinct bearing on clinical behavior or prognosis, and more than one morphologic pattern may be present in a given tumor. Although the typical ameloblastoma is a histologically benign and slowly growing tumor, it has the capacity to cause destructive local growth and even death by invasion of vital structures.[1] Rare variants are malignant ameloblastoma and ameloblastic carcinoma (AC). The classification system by World Health Organization (WHO) defines malignant ameloblastoma as an ameloblastoma, which has metastasized but exhibits the well-differentiated morphologic features of a typical ameloblastoma in both the primary and metastatic sites.[1] In comparison, AC is the pathologic designation describing an ameloblastoma with areas of obvious histologic malignancy. AC may arise de novo or from transformation of a long-standing primarily benign lesion, usually secondary to recurrences associated with multiple surgical procedures or radiation therapy.[1] The incidence of AC is greater than that of malignant ameloblastoma by a 2:1 ratio and carries a bad prognosis.[2]

CASE REPORT

A 64-year-old male presented with toothache since 4 months in the left upper molar, following which tooth extraction was done. This resulted in failure of healing of the extraction socket and a soft tissue growth over it 3 months post extraction, causing a left mandibular swelling. Incisional biopsy was done and a diagnosis of ameloblastoma was made following which surgical excision of the tumor was done. The patient presented with recurrence of the swelling after 2 years. Clinical examination revealed a diffuse, non-tender swelling of the buccal sulcus of the mandible along with an intraoral sinus. The skin overlying the swelling seemed normal. No lymph nodes were palpable on neck examination. Radiological examination of head and neck revealed radiolucent lesion involving the body and ramus of the mandible, with ill-defined margins, along with destruction of the cortical plate. Chest X-ray and further clinical examination failed to reveal any metastasis. Incisional biopsy was done from the lesion. On microscopic examination, the neoplasm was observed to be containing follicles and cords of cohesive, poorly differentiated malignant cells with a basaloid appearance [Figure 1]. The cells displayed pleomorphism with hyperchromatic nuclei with nucleoli and scant cytoplasm [Figures 2 and 3]. Mitosis was frequent. No stellate reticulum or squamous metaplasia was identified. Thus, a diagnosis of AC was made.
Figure 1

Low-power view showing the follicular arrangement of cells and the overall basophilic staining quality (H&E, ×100)

Figure 2

High power of the follicle and pleomorphic cells with prominent nucleoli (H&E, ×400)

Figure 3

High-power view showing pleomorphic cells and abundant mitoses (H&E, ×400)

Low-power view showing the follicular arrangement of cells and the overall basophilic staining quality (H&E, ×100) High power of the follicle and pleomorphic cells with prominent nucleoli (H&E, ×400) High-power view showing pleomorphic cells and abundant mitoses (H&E, ×400)

DISCUSSION

Ameloblastomas constitute a group of particularly interesting lesions because they display origin from embryologic components of the developing tooth germ. Although very rare when viewed in the context of the human tumor pathology, ameloblastoma represents the most common tumor derived from tooth epithelial components, representing between 13% and 24% of the odontogenic neoplasms.[3] Malignant epithelial odontogenic tumors, which include malignant ameloblastoma, AC, primary intraosseous squamous cell carcinoma, clear cell odontogenic tumor and malignant epithelial ghost cell tumor, are very rare.[4] In 1983, Shafer introduced the term “ameloblastic carcinoma” to describe ameloblastomas in which there had been histologic malignant transformation.[2] Carcinomas associated with ameloblastoma have had several terminologies within the medical literature, thus posing a problem in accurately separating malignant ameloblastoma from AC. Several authors have attempted to make a distinction between these two entities because AC is clinically more aggressive. These definitions include a well-differentiated ameloblastoma with histologically malignant epithelial component; a tumor with histologic evidence of malignancy and features of ameloblastoma and concomitant squamous cell carcinoma; a tumor with combined features of an ameloblastoma with less differentiated areas; and any ameloblastoma with histologic evidence of malignancy in the primary tumor or the recurrent tumor, irrespective of whether the tumor has metastasized.[1] AC is a very rare tumor with an incidence of less than 1%. It occurs in a wide range of age groups with a mean age of 30.1 years. There is no apparent sex predilection. The most commonly involved area is the posterior portion of the mandible.[2] Unusual locations are maxilla, nasal cavity and anterior skull.[56] Our patient was 64 years old and presented with swelling of the left mandible. The most common signs include swelling, associated pain, rapid growth, trismus and dysphonia. Perforation of the cortical plate, extension into surrounding soft tissue, numerous recurrent lesions and metastasis, usually to cervical lymph nodes, can be associated with AC.[2] The radiographic appearance of the lesion is usually similar to that of ameloblastoma except for the presence of focal radiopacity, apparently reflecting dystrophic calcification.[27] The case described in this report also showed similar radiological features with destruction of the cortical plate. Histologically, the tumor cells resemble the cells seen in ameloblastoma but show cytologic atypia, cellular pleomorphism, nuclear hyperchromasia, mitoses, vascular and neural invasion.[7] Similar features were noted in this case. AC can recur locally 0.5–11 years after definitive therapy. Distant metastasis may appear 4–12 years postoperatively and is common in lung, bone, liver and brain.[6] Chromosomal imbalances in ameloblastomas are reported to be rare, with losses in chromosomes 22 and 10 being most frequent. Aneuploidy is more common in AC and may predict malignant potential.[3] Differential diagnosis of AC includes primary intra-alveolar epidermoid carcinoma, acanthomatous ameloblastoma, keratoameloblastoma, squamous odontogenic tumor and metastatic tumors from lung, breast and gastrointestinal tract.[2] To conclude, ameloblastoma shows a variety of histologic and biologic behavior ranging from benign to frank malignancy. Although AC is rare, it is important to rule it out in patients presenting with toothache or mobile teeth in association with persistent jaw swelling, pain and rapid growth through prompt radiological and histopathologic investigations. Cases of ameloblastomas should thus be studied carefully to detect subtle changes in histology that may predict aggressive behavior and bad prognosis.
  6 in total

1.  Ameloblastic carcinoma arising from anterior skull base.

Authors:  Samet Ozlugedik; Muge Ozcan; Olca Basturk; Orgun Deren; Erkan Kaptanoglu; Gökhan Adanali; Adnan Unal
Journal:  Skull Base       Date:  2005-11

2.  Ameloblastic carcinoma: report of an aggressive case with multiple bony metastases.

Authors:  Rajiv Datta; Janet S Winston; Gustavo Diaz-Reyes; Thom R Loree; Larry Myers; M Abraham Kuriakose; Nestor R Rigual; Wesley L Hicks
Journal:  Am J Otolaryngol       Date:  2003 Jan-Feb       Impact factor: 1.808

Review 3.  Ameloblastic carcinoma of the maxilla: a report of 3 cases.

Authors:  P Infante-Cossio; J M Hernandez-Guisado; P Fernandez-Machin; A Garcia-Perla; A Rollon-Mayordomo; J L Gutierrez-Perez
Journal:  J Craniomaxillofac Surg       Date:  1998-06       Impact factor: 2.078

Review 4.  Ameloblastic carcinoma: case report and literature review.

Authors:  Sylvie Louise Avon; John McComb; Cameron Clokie
Journal:  J Can Dent Assoc       Date:  2003-10       Impact factor: 1.316

5.  Allelic loss of tumor suppressor genes in ameloblastic tumors.

Authors:  Laurentia Nodit; Leon Barnes; Esther Childers; Sydney Finkelstein; Patricia Swalsky; Jennifer Hunt
Journal:  Mod Pathol       Date:  2004-09       Impact factor: 7.842

6.  Ameloblastic carcinoma: a case report.

Authors:  Veena Naik; Alka D Kale
Journal:  Quintessence Int       Date:  2007 Nov-Dec       Impact factor: 1.677

  6 in total
  1 in total

1.  Usefulness of 11C-methionine positron emission tomography for detecting intracranial ameloblastic carcinoma: A case report.

Authors:  Akira Tempaku; Yoshinobu Takahashi; Hidetoshi Ikeda; Shigeru Yamauchi; Takashi Gotoh; Nobuyuki Bandoh; Syujirou Makino; Takuji Shimada; Hajime Kamada
Journal:  Oncol Lett       Date:  2014-07-15       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.